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Background: Bleeding following Transcatheter Aortic Valve Implantation (TAVI) still remain frequent and potentially harmful being associated with 
unfavorable prognosis. A proper heparin dose adjustment can be advocated in order to reduce the risk of potential overdosing in such a frail patient 
population.Therefore, the aim of this study is to evaluate the impact of the ACT guided heparin administration on bleeding events after trans-femoral 
(TF) TAVI.
methods: From November 2007 to June 2012, all patients with symptomatic severe aortic stenosis underwent to TF-TAVI in our center were 
analyzed. Intra-procedural heparin administration was performed upon operator discretion according to two modalities: baseline ACT guidance 
(ACT-guided) or body weight (ACT-non guided) groups. The primary study objective was 30-day cumulative rate of bleeding defined by Valve Academic 
Research Consortium (VARC) criteria. Secondary study objectives were all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, 
vascular complications and acute kidney failure at 30-day according to the VARC.
results: A total of 362 patients undergoing to TF-TAVI: 174 (48.1%) in ACT guided vs. 188 (51.9%) patients in ACT-non guided group. No 
statistically significant differences in clinical and procedural characteristics were observed between study groups. Bleeding occurred in 167 (46.1%) 
patients: 59 (16.3%) had a life-threatening bleeding, 76 (21.0%) a major bleeding and 32 (8.8%) a minor bleeding. A significant lower occurrence 
of any bleeding was observed in ACT guided group (26.9% vs. 73.1%, p<0.001), mainly driven by a lower occurrence of life-threatening (35.6% vs. 
64.4%, p=0.04) and major bleeding (17.1% vs. 82.9%, p<0.001). However, no differences were noted regarding the secondary study objectives. 
Lack of ACT guidance [OR 4.10, 95% CI (2.03-8.27), p<0.001] and creatinine clearance [OR 0.98, 95%CI (0.97-0.99), p=0.04] were found to be 
predictors of 30-day major bleeding.
conclusions: Heparin dose adjustment using ACT guided strategy has shown to reduce 30-day life threatening and major bleeding after TF-TAVI.
